Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study


CHANAN-KHAN A., CRAMER P., Demirkan F., Fraser G., SILVA R. S. , GROSICKI S., ...Daha Fazla

LANCET ONCOLOGY, cilt.17, ss.200-211, 2016 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 17 Konu: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/s1470-2045(15)00465-9
  • Dergi Adı: LANCET ONCOLOGY
  • Sayfa Sayıları: ss.200-211

Özet

Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.